Publication | Open Access
Phase 2b Controlled Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis
392
Citations
27
References
2018
Year
M72/AS01<sub>E</sub> provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598 .).
| Year | Citations | |
|---|---|---|
Page 1
Page 1